Hengrui Pharmaceuticals (恒瑞医药)
China's largest innovative pharmaceutical company by R&D spending, focused on oncology, autoimmune, and metabolic disease drug development.
Signal history
4 totalHengrui Pharma's Eltrombopag Approved for First-Line Anemia Treatment
Hengrui Pharmaceuticals has received approval for a new indication for its innovative drug, Eltrombopag. The approval allows Eltrombopag to be used as a first-line treatment for severe aplastic anemia. This expanded indication is a significant development, providing a crucial new therapeutic option for patients with this serious hematological condition. It underscores Hengrui's commitment to advancing treatments for blood disorders and improving patient outcomes.
Hengrui Pharma's PNH Drug Marketing Application Accepted by Regulators
Hengrui Pharmaceuticals announced that its novel drug, Fumaric Acid Likoncopan Capsules, has received acceptance for its marketing application by regulatory authorities. This drug is intended for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have undergone prior treatment. The acceptance marks a significant step forward in the drug's development and potential market entry, offering a new therapeutic option for PNH patients.
Hengrui Pharmaceuticals Declares RMB 2.0 Dividend Per 10 Shares for FY2024
Jiangsu Hengrui Pharmaceuticals Co., Ltd. has announced its dividend declaration for the financial year 2024. The company will pay a dividend of RMB 2.0 per 10 shares, with an entitlement date of May 23, 2025. The total cash bonus for this period amounts to RMB 127,413.02 million. This marks a continuation of the company's dividend payout policy.
Hengrui Pharma's PNH Drug Application Accepted for Treatment
Hengrui Pharmaceuticals announced that its novel drug, Fumaric Acid Licancopan Capsules, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients who have undergone prior treatment, has received acceptance for its marketing application. This marks a significant step towards potential market entry for this new therapeutic option.
Key Changes (30d)
Hengrui Pharma's Novel Drug Application for PNH Accepted by Regulators
Hengrui Pharmaceuticals' novel drug Fumaric Acid Likoncopan Capsules for paroxysmal nocturnal hemoglobinuria (PNH) has had its marketing application accepted by Chinese regulators.
Hengrui Pharma's New Indication for Eltrombopag Approved for Anemia
Hengrui Pharmaceuticals' Eltrombopag approved for first-line treatment of severe aplastic anemia, expanding patient options.
Hengrui Pharma's Novel Drug Application Accepted for PNH Treatment
Hengrui Pharmaceuticals' novel drug Fumaric Acid Licancopan Capsules for PNH treatment receives marketing application acceptance, moving closer to potential market entry.
Hengrui Pharmaceuticals Declares Dividend for FY2024
Hengrui Pharmaceuticals declared a dividend of RMB 2.0 per 10 shares for FY2024, totaling RMB 127,413.02 million, with an entitlement date of May 23, 2025.
Source Language Distribution
Source Tier Distribution
100% officialStrategic themes and signal pattern
Strategic Themes
Recent Signal Pattern
Why this company matters
Hengrui is the benchmark for China's pharmaceutical innovation capability. Its transition from generics to innovative drugs mirrors the broader evolution of China's pharma industry. Hengrui's international licensing deals and clinical trials are key indicators of whether Chinese-developed drugs can compete globally.
- Key domain relevance: Oncology drugs, Innovative drug R&D, International licensing
- Active monitoring with 4 signals in the last 30 days across 2 tracked sources.
Channel Context
Channel context will be available once this company is assigned to a primary channel.
Market Context
This company operates in one of SigFact's strongest advantage markets, where official updates often surface first in local language.
See recent signals in this marketContinue monitoring Hengrui Pharmaceuticals (恒瑞医药)
Follow this company, add it to your watchlist, or explore its signal stream to stay informed.